Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 84.05% is 119% above its 5-year average of -435.89%, near the high end of its 5-year range (-759516.67%–213.91%).
122.43% above its 12-month average of -374.73%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
84.05%
GROSS MARGIN AVG TTM
-374.73%
GROSS MARGIN AVG 3Y
-491.53%
GROSS MARGIN AVG 5Y
-435.89%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+122.43%
CURRENT VS 3Y AVG
+117.10%
CURRENT VS 5Y AVG
+119.28%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
59.92%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
+40.26%
vs the sector median at left
Beam Therapeutics Inc.
Market Cap
$2.51B
Gross Margin
84.05%
TTM Avg
-374.73%
3Y Avg
-491.53%
5Y Avg
-435.89%
Market Cap
$2.74B
Gross Margin
58.69%
TTM Avg
59.64%
3Y Avg
63.22%
5Y Avg
64.62%
Market Cap
$2.14B
Gross Margin
-61.96%
TTM Avg
-19.42%
3Y Avg
-14.39%
5Y Avg
23.74%
Market Cap
$1.73B
Gross Margin
49.52%
TTM Avg
50.81%
3Y Avg
52.12%
5Y Avg
52.25%
Market Cap
$1.72B
Gross Margin
76.47%
TTM Avg
79.35%
3Y Avg
79.86%
5Y Avg
39.87%
Market Cap
$1.00B
Gross Margin
73.53%
TTM Avg
70.13%
3Y Avg
70.04%
5Y Avg
68.74%
Market Cap
$472.39M
Gross Margin
42.92%
TTM Avg
41.39%
3Y Avg
40.24%
5Y Avg
40.24%
Market Cap
$397.55M
Gross Margin
77.34%
TTM Avg
76.74%
3Y Avg
77.57%
5Y Avg
77.57%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | $2.51B | 84.05% | -374.73% | -491.53% | -435.89% |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 58.69% | 59.64% | 63.22% | 64.62% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.14B | -61.96% | -19.42% | -14.39% | 23.74% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 49.52% | 50.81% | 52.12% | 52.25% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | 76.47% | 79.35% | 79.86% | 39.87% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | 73.53% | 70.13% | 70.04% | 68.74% |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | 42.92% | 41.39% | 40.24% | 40.24% |
| NRC Health (NRC)vs › | $459.30M | 56.33% | 58.27% | 60.30% | 61.48% |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | 77.34% | 76.74% | 77.57% | 77.57% |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
84.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 65.16% |
| 2025-12-31 | 95.03% |
| 2025-09-30 | -1031.87% |
| 2025-06-30 | -1101.96% |
| 2025-03-31 | -1222.84% |
| 2024-12-31 | -237.39% |
| 2024-09-30 | -560.58% |
| 2024-06-30 | -639.39% |
| 2024-03-31 | -1044.64% |
| 2023-12-31 | 55.70% |
| 2023-09-30 | -481.92% |
| 2023-06-30 | -385.23% |
| 2023-03-31 | -311.62% |
| 2022-12-31 | -330.91% |
| 2022-09-30 | -439.83% |
| 2022-06-30 | -347.73% |
| 2022-03-31 | -675.74% |
| 2021-12-31 | 213.91% |
| 2021-09-30 | -7058.98% |
| 2021-06-30 | -759516.67% |
| 2021-03-31 | -3168333.33% |
| 2020-12-31 | -540750.00% |
| 2020-09-30 | -496983.33% |
| 2020-06-30 | -322466.67% |
| 2020-03-31 | -359050.00% |
| 2019-12-31 | -336850.00% |
| 2019-09-30 | -208950.00% |
| 2019-06-30 | -211233.33% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
